Longevity is ceasing to be science fiction and becoming preventive medicine. In the last three years we have seen more advances in anti-ageing biomedicine than in the three decades before: from the first clinical trial of rapamycin in healthy humans to senolytic therapies that selectively eliminate zombie cells.
But what's really exciting is not what we already have—NAD+, resveratrol, collagen—but what's currently in the pipeline: compounds in phase II/III that could reach the market in the next 2-4 years, gene therapies that already work in mice, and personalised protocols based on epigenetic analysis.
In this article we'll analyse the most promising longevity trends that are about to go mainstream, separating solid science from marketing smoke. From oral rapamycin to home epigenetic clocks, through second-generation senolytics already in human trials.
- Oral rapamycin will move from off-label to authorised preventive use in healthy populations
- Second-generation senolytics (not dasatinib+quercetin) will arrive as food supplements
- Epigenetic analysis will become as routine as a blood test
- Gene therapies for rejuvenation will move from mice to first humans
- Combined protocols with real data will replace the 'take 30 things' approach
Rapamycin: from transplant drug to preventive protocol
Rapamycin (sirolimus) has been used for 25 years as an immunosuppressant in transplants. What's new is that several research groups are testing it in healthy humans for longevity, with preliminary results replicating what's been seen in mice: median lifespan extension of 15-20%.
The mechanism is solid: it inhibits mTOR, a master regulator of ageing that controls protein synthesis, autophagy and cellular metabolism. When mTOR is hyperactive (Western diet, sedentary lifestyle), cells accumulate waste and age faster. Rapamycin slows that process.
What's coming:
- Ongoing clinical trials (TAME trial, Longevity AI) with thousands of participants
- Optimised intermittent dosing (1-2 times/week vs. daily) to minimise side effects
- More bioavailable oral formulations than original sirolimus
- Combined protocols with strength training to maintain muscle mass
But watch out: rapamycin is not for everyone. It can affect wound healing, increase risk of mild infections and has interactions with many drugs. Most likely it will arrive as a supervised medical protocol, not as an over-the-counter food supplement.
Second-generation senolytics: beyond dasatinib + quercetin
Senolytics eliminate senescent cells (zombie cells that stopped dividing but don't die and secrete inflammatory factors). The dasatinib+quercetin combination works in studies, but has problems: dasatinib is a chemotherapy drug with adverse effects and quercetin has very low bioavailability.
What's coming are second-generation senolytics designed specifically to eliminate senescent cells without affecting healthy ones:
Optimised fisetin: fisetin (a flavonoid) showed senolytic activity in mice, but the standard version has 5-10% bioavailability. New liposomal or nano-encapsulated formulations achieve 40-60%.
Synthetic peptides: compounds such as BCL-xL inhibitor (Senolytic Therapeutics) that induce selective apoptosis in senescent cells. Already in phase II with humans.
Validated combinations: protocols that alternate senolytics (to clear zombie cells) with senostatics (that block inflammation from senescent cells without killing them). Safer than continuous high doses.
Realistic timeline: first optimised senolytic food supplements in 18-24 months, medical therapies with BCL-xL in 3-4 years. The key will be finding the optimal frequency (cycles every 3-6 months? annually?) to clear zombie cells without stressing the system.
Epigenetic clocks: your real biological age at home
Epigenetic clocks (Horvath, GrimAge, DunedinPACE) measure your real biological age—not your chronological age—by analysing DNA methylation patterns. Until now they cost £250-450 and were only available in specialised laboratories.
What's coming:
- Home kits under £80 that you analyse yourself with saliva or capillary blood
- Integration with wearables: epigenetic clocks combined with data from Oura, Whoop, etc.
- Personalised protocols: "your epigenetic clock says your liver is 52 years old but your vascular system is 38 → protocol X"
- Quarterly monitoring: measure real impact of your interventions (did that NAD+ protocol work? You'll know in 90 days)
The cultural shift will be enormous. Imagine doing biological age tests like you do cholesterol tests today. We'll move from "I take supplements because an influencer said so" to "I adjust my protocol quarterly based on my epigenetic clock".
But be careful with over-interpretation: these clocks measure statistical correlations, not causality. If your GrimAge goes up 2 years in a month, it could be statistical noise, temporary stress or recent infection. The key will be interpreting trends over 6-12 months, not obsessing over monthly fluctuations.
Gene therapies: from mice to first humans
Gene therapies that reversed biological age in mice are starting human trials. We're not talking about CRISPR editing your genome (that will take decades to reach anti-ageing), but partial reprogramming therapies.
The concept: Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) can reprogramme adult cells to a pluripotent (embryonic) state. But complete reprogramming creates cancer. The magic is in PARTIAL reprogramming: activating these factors briefly rejuvenates cells without dedifferentiating them.
Altos Labs, Calico and several start-ups have in their pipeline:
- AAV therapies (adeno-associated viruses) that deliver reprogramming factors to specific tissues
- Ocular reprogramming: reversing glaucoma and macular degeneration (phase I/II trials)
- Liver rejuvenation: improving liver function in people >60 (advanced preclinical)
- Systemic epigenetic therapy: reprogramming multiple tissues via infusion (phase I in 2-3 years)
Realistic outlook: the first therapies will arrive for specific medical indications (glaucoma, liver fibrosis) in 3-5 years. General use for longevity will take 8-12 years and will be expensive (£40-160K probably). But once the first one works, the price will fall like it did with statins.
Combined protocols with real data: goodbye to 'take 30 things'
Current biohacking trend is to stack 20-30 supplements "just in case". What's coming is the opposite: minimalist protocols of 3-6 ingredients with real synergy data.
::pull-quote{text='The future of longevity is not taking more things, it's taking the right things in the right sequence.' source='Dr. David Sinclair, Harvard Medical School'} ::
Examples of combined protocols emerging from clinical trials:
Optimised NAD+ protocol: not just NMN or NR, but NMN + pterostilbene + glycine (which recycles NAD+). Recent meta-analyses show 40-60% increase in blood NAD+ vs. 20-30% with NMN alone.
Senescence stack: senolytic (fisetin every 3 months) + daily senostatic (liposomal quercetin) + mitochondrial support (CoQ10, PQQ). Reduces inflammatory markers 35% more than senolytics alone.
Collagen + bioavailability protocol: hydrolysed collagen + vitamin C + hyaluronic acid + copper (cofactor of collagen-synthesising enzymes). Improves skin elasticity 28% vs. 12% with collagen alone.
The key is that these protocols are being validated in trials with real biomarkers (not just "I feel better"). The future will be less "take this because Bryan Johnson does" and more "your blood work shows X → protocol Y for 90 days → retest".
How to prepare for longevity's future (today)
Whilst waiting for oral rapamycin and gene therapies, there are fundamentals you can implement now that will remain relevant in any future:
1. Establish your biological baseline: get a complete blood test (blood work, metabolism, inflammation) and, if you can, an epigenetic clock. Without a baseline, you won't know if what you do works.
2. Master the non-negotiables: deep sleep 7-8h, strength training 2-3x/week, protein 1.6-2g/kg, circadian fasting 12-14h. No future therapy will compensate for sleeping 5 hours.
3. Minimalist protocol, not maximalist: choose 3-5 interventions with solid evidence and do them well. Better magnesium glycinate every night than 15 supplements you take when you remember.
4. Measure, adjust, repeat: retest every 3-6 months. If your high-sensitivity CRP doesn't drop, your anti-inflammatory protocol isn't working. If your HbA1c rises, your intermittent fasting isn't working.
At Longevitalis we've developed 3 complementary protocols—LongeviNocturno for nocturnal repair, Vitalis Renova+ for morning cellular renewal and LongeviSkin for skin from within. All with clinical doses, formulated in Spain under GMP and with only ingredients that have solid evidence.
They're not 30 products because you don't need 30 things. You need the 3-4 right interventions done consistently. That philosophy won't change even when rapamycin and gene therapies arrive. Why Longevitalis only sells 3 products (and not 30) explains why.
The protocols are at longevitalis.com/en/products. The idea is for them to be your solid foundation whilst future therapies arrive.
Extreme personalisation: from 'take this' to 'your unique protocol'
Current longevity medicine is generalised: "take vitamin D, take omega-3, take collagen". The future will be hyper-personalised based on:
Genomics: not just recreational 23andMe, but analysis of genetic variants affecting nutrient metabolism. If you have the MTHFR C677T polymorphism (40% of the population), you need methylfolate instead of standard folic acid.
Microbiome: analysis of your gut microbiota to know which specific prebiotics/probiotics you need. Recent meta-analyses show that 'universal' probiotics work in only 30% of people—the rest need personalised strains.
Metabolomics: analysis of metabolites in blood/urine that reveal deficiencies before they show up in standard blood work. For example, detecting carnitine deficiency even though your serum carnitine levels are 'normal'.
What's coming:
- AI-powered apps that analyse your blood work + genomics + wearables and suggest personalised protocol
- Bespoke supplements: custom formulations made in pharmacies according to your profile (already exists in the US, coming to Europe)
- Continuous monitoring: continuous glucose monitors, real-time metabolite analysis via wearables
The risk: paralysing over-personalisation. If you change your protocol every week because an app says your omega-6/omega-3 ratio went up 0.2 points, you'll never know what works. Useful personalisation will be adjustments every 3-6 months based on trends, not daily micro-optimisation.
Next-generation NAD+: beyond NMN and NR
NAD+ (nicotinamide adenine dinucleotide) is essential for mitochondria, DNA repair and sirtuins. It drops 50% between ages 40-60. NMN and NR work, but have limitations: 30-50% bioavailability, short half-life, inconsistent effects between people.
What's in the pipeline:
Fourth-generation precursors: compounds like NRH (reduced nicotinamide riboside) that bypass enzymes degrading NMN/NR. Preliminary studies show NAD+ increase of 80-100% vs. 40-60% with NMN.
Endogenous biosynthesis activators: instead of giving external NAD+, compounds that activate the salvage pathway (internal NAD+ recycling). More sustainable long-term.
Liposomal formulations: NMN/NR encapsulated in liposomes to protect from gastric degradation. Bioavailability increases from 40% to 70-80%.
Optimised combinations: NAD+ + resveratrol + pterostilbene (sirtuin activators) in specific ratios. Validated synergy: 40% more SIRT1 activation than individual components.
Timeline: liposomal formulations already available (prices 2-3x vs. standard). Fourth-generation precursors in 12-18 months. Endogenous activators in 2-3 years.
Metformin: from off-label to authorised preventive use
Metformin (antidiabetic) has been used off-label for longevity for years. What's new is the TAME trial (Targeting Aging with Metformin), a trial with 3,000 participants seeking FDA authorisation for metformin as an 'anti-ageing drug' in non-diabetic populations.
If TAME succeeds (results expected in 18-24 months), metformin will be the first officially authorised drug to slow ageing. That would open the regulatory door for rapamycin, senolytics and others.
But metformin has limitations:
- Interferes with muscle hypertrophy: partially blocks mTOR, which can reduce strength gains
- B12 deficiency: 10-30% of users develop deficiency after 2-3 years
- GI problems: 20-30% experience diarrhoea/nausea, especially initially
What's coming are optimised versions: extended-release metformin with fewer GI effects, combinations with leucine to preserve muscle mTOR, and cycling protocols (5 days ON / 2 OFF) to maintain benefits without blocking hypertrophy.
Mitochondria: from CoQ10 to replacement therapy
Mitochondria (cellular energy centres) accumulate damage with age. 70% of your energy capacity at age 70 is due to mitochondrial dysfunction, not just 'general ageing'.
Current: CoQ10, PQQ, urolithin A (all help, but are palliative).
What's coming:
Mitochondrial replacement therapy: injection of healthy mitochondria from autologous stem cells (your own stem cells) into aged tissues. Already works in animal models, first human trials in 2-3 years.
Mitochondrial peptides: compounds like SS-31 (elamipretide) that repair damaged mitochondrial membranes. In phase II/III for heart failure, could reach preventive use in 3-4 years.
NAD+ + healthy mitochondria: protocols combining NAD+ boosters (for energy) with induced mitophagy (selective autophagy of damaged mitochondria via fasting or spermidine) followed by exercise (which creates new mitochondria). The sequence matters: first you clean the broken ones, then you create new ones.
The vision at 5-8 years: your 'mitochondrial age' will be a standard biomarker (tests exist but are expensive). Personalised protocols based on mitochondrial function: if in 20th percentile for your age, aggressive protocol; if 80th percentile, maintenance.
Frequently Asked Questions (FAQ)
When will these treatments be available to the general public?
Realistic timeline: optimised senolytics and advanced NAD+ formulations in 12-24 months. Home epigenetic clocks in 18 months. Rapamycin for longevity (supervised medical use) in 2-3 years. Gene therapies for specific indications in 3-5 years, general use in 8-12 years. Good news: what we already know (sleep, exercise, basic nutritional protocol) still accounts for 70% of results.
Will these treatments work for someone aged 50 or only for young people?
Most are designed specifically for people aged 45-50+, when biological ageing accelerates. Epigenetic clocks show that decline accelerates from age 44 (second inflection point, after puberty). Senolytics, for example, have little effect in people under 40 because there are barely any senescent cells. The optimal window for most interventions is 45-65 years: old enough to benefit, young enough to reverse damage.
How much will these protocols cost when available?
Projection at 3-5 years: epigenetic clocks <£80/test, optimised senolytics £65-120/month, next-generation NAD+ £95-160/month, supervised rapamycin £80-145/month (in Spain probably partially covered by private insurance if authorised for prevention). Gene therapies will be expensive initially (£40-160K) but will fall to <£8K in 10-15 years following typical biotech learning curves. Effective basic protocols will remain accessible: <£120/month.
Can I start preparing now or should I wait for these to come out?
Start NOW with fundamentals: complete baseline blood work (blood work, metabolism, inflammation, hormonal), optimise deep sleep with sleep hygiene protocol, strength training 2-3x/week, anti-inflammatory nutritional protocol. Consider validated basic supplementation (magnesium, omega-3, vitamin D according to your levels). 80% of benefits come from these fundamentals; advanced therapies will add the extra 20%. Those who reach these therapies with optimised fundamentals will get 3-4x better results than those using them to compensate for poor habits.
Is it safe to be an 'early adopter' of these treatments?
Depends on the treatment. Epigenetic clocks: completely safe (they only measure, don't intervene). Optimised senolytics and next-generation NAD+: low-to-moderate risk if from GMP manufacturers with third-party testing. Rapamycin: only under medical supervision, has real interactions and adverse effects. Gene therapies: wait for phase III completion (still years away). Rule of thumb: if it has decades of use in another indication (metformin, rapamycin), the safety profile is known; if it's entirely new, wait until at least phase II finishes.
Will these advances make current supplements like collagen or magnesium obsolete?
No. The biological fundamentals don't change: you need magnesium for 300+ enzyme reactions, you need collagen for extracellular matrix, you need omega-3 for cell membranes. Advanced therapies will add to fundamentals, not replace them. Think of it this way: antibiotics didn't make hygiene obsolete; they accelerated it. Gene therapies won't make deep sleep or protein nutrition obsolete; they'll let you leverage them better. Longevity will remain a pyramid: solid base of habits + basic supplementation + (new) advanced therapies at the top.
Conclusion: the future is incremental, not magical
Longevity won't have a 'before/after' moment like the iPhone. It will be an accumulation of small advances: senolytics reducing inflammation 30%, rapamycin extending median lifespan 10-15%, gene therapies reversing 5-8 years of ocular age, epigenetic clocks measuring all of it.
What's exciting is that these advances are happening in parallel and will potentiate each other. An optimised protocol in the next 3-5 years could combine: epigenetic baseline → personalised NAD+ protocol + senolytics + metformin → quarterly retest → adjustments based on data → specific gene therapy when available for your weak point (ocular, liver, cardiovascular).
But none of this works without fundamentals. Someone reaching these therapies sleeping 5 hours, eating ultra-processed food and sedentary will get 20% of the benefit of someone reaching them with optimised sleep, regular strength training and an anti-inflammatory nutritional protocol.
The future of longevity is not choosing between habits or technology. It's solid habits + intelligent supplementation + advanced therapies when validated. In that order.
At Longevitalis we'll keep documenting these advances as solid studies emerge. Meanwhile, the protocols we have—LongeviNocturno for restorative sleep, Vitalis Renova+ for cellular renewal, LongeviSkin for skin from within—are designed to be your solid foundation, the one that will remain relevant regardless of which therapies emerge in the coming years.
Because ultimately, longevity is not about living to 120 taking 47 pills. It's about reaching 70-80-90 with energy, mental clarity and physical capacity to enjoy those years. And that starts today, with simple, consistent decisions.
Medical disclaimer: This information is for educational purposes and does not replace professional medical advice. Consult your doctor before starting any protocol, especially if taking medication or having pre-existing conditions. Therapies mentioned in research stages are not authorised for general use and their safety/efficacy profiles are not fully established.
